Overview

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the analgesic efficacy of ADL5747 in participants with postherpetic neuralgia (PHN). The secondary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of ADL5747.
Phase:
Phase 2
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Collaborator:
Pfizer
Treatments:
Pregabalin